Unknown

Dataset Information

0

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.


ABSTRACT: BACKGROUND:Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. OBJECTIVES:The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality. METHODS:A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3. RESULTS:The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both). CONCLUSIONS:Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.

SUBMITTER: Ghorbani A 

PROVIDER: S-EPMC6516745 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.

Ghorbani Anahita A   Bhambhani Vijeta V   Christenson Robert H RH   Meijers Wouter C WC   de Boer Rudolf A RA   Levy Daniel D   Larson Martin G MG   Ho Jennifer E JE  

Journal of the American College of Cardiology 20181201 25


<h4>Background</h4>Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear.<h4>Objectives</h4>The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality.<h4>Methods</h4>A tot  ...[more]

Similar Datasets

| S-EPMC6248104 | biostudies-literature
| S-EPMC7670497 | biostudies-literature
| S-EPMC6202173 | biostudies-literature
| S-EPMC6898842 | biostudies-literature
| S-EPMC3727342 | biostudies-literature
| S-EPMC4007212 | biostudies-literature
| S-EPMC6802267 | biostudies-literature
| S-EPMC5860547 | biostudies-other
| S-EPMC4142588 | biostudies-other
| S-EPMC7106714 | biostudies-literature